Aadi Bioscience amends FYARRO supply agreement with Fresenius Kabi, extends term to July 31, 2024

Whitehawk Therapeutics, Inc.

Amendment effective March 31, 2024 extends supply agreement for FYARRO through July 31, 2024 (or later agreed date).
Revised pricing, forecasting, compliance terms, and minimum purchase obligations for FYARRO from Fresenius Kabi.
Contains other customary terms for biotech manufacturing; full amendment to be filed in subsequent periodic report.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Whitehawk Therapeutics, Inc. amended Amendment No.2 (the "Amendment") to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the "Agreement") with Fresenius Kabi, LLC (effective 2024-03-31).

Action: amendment
Agreement: supply
Counterparty: Fresenius Kabi, LLC
Effective: 2024-03-31

Exact text from the filing

On April 1, 2024, Aadi Bioscience, Inc. (the “Company”) entered into Amendment No.2 (the “Amendment”) to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the “Agreement”) with Fresenius Kabi, LLC (“Fresenius Kabi”). The Amendment is effective as of March 31, 2024.

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-014876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.